Shanghai Runda Medical Technology Co., Ltd. (603108.SS)
CNY 17.08
(0.47%)
CNY 17.08
(0.47%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.14 Billion CNY | -13.28% |
| 2022 | 10.49 Billion CNY | 18.45% |
| 2021 | 8.86 Billion CNY | 25.33% |
| 2020 | 7.06 Billion CNY | 0.24% |
| 2019 | 7.05 Billion CNY | 18.24% |
| 2018 | 5.96 Billion CNY | 38.1% |
| 2017 | 4.31 Billion CNY | 99.51% |
| 2016 | 2.16 Billion CNY | 32.91% |
| 2015 | 1.62 Billion CNY | 19.89% |
| 2014 | 1.35 Billion CNY | 32.42% |
| 2013 | 1.02 Billion CNY | 32.83% |
| 2012 | 772.33 Million CNY | 22.31% |
| 2011 | 631.45 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.06 Billion CNY | -8.07% |
| 2024 Q2 | 2.06 Billion CNY | 0.09% |
| 2024 Q3 | 2.03 Billion CNY | -1.48% |
| 2023 Q3 | 2.36 Billion CNY | 1.1% |
| 2023 Q4 | 2.24 Billion CNY | -5.37% |
| 2023 FY | 9.1 Billion CNY | -13.28% |
| 2023 Q1 | 2.17 Billion CNY | -23.85% |
| 2023 Q2 | 2.34 Billion CNY | 7.58% |
| 2022 Q2 | 2.59 Billion CNY | 19.54% |
| 2022 Q1 | 2.16 Billion CNY | 3.91% |
| 2022 FY | 10.49 Billion CNY | 18.45% |
| 2022 Q4 | 2.86 Billion CNY | -0.45% |
| 2022 Q3 | 2.87 Billion CNY | 10.83% |
| 2021 Q2 | 2.26 Billion CNY | 9.95% |
| 2021 Q4 | 2.08 Billion CNY | -14.46% |
| 2021 Q3 | 2.43 Billion CNY | 7.51% |
| 2021 FY | 8.86 Billion CNY | 25.33% |
| 2021 Q1 | 2.06 Billion CNY | -3.74% |
| 2020 Q3 | 1.98 Billion CNY | 20.57% |
| 2020 FY | 7.06 Billion CNY | 0.24% |
| 2020 Q4 | 2.14 Billion CNY | 8.19% |
| 2020 Q2 | 1.64 Billion CNY | 26.54% |
| 2020 Q1 | 1.29 Billion CNY | -30.13% |
| 2019 Q2 | 1.76 Billion CNY | 15.17% |
| 2019 Q1 | 1.53 Billion CNY | -5.95% |
| 2019 FY | 7.05 Billion CNY | 18.24% |
| 2019 Q4 | 1.85 Billion CNY | -2.05% |
| 2019 Q3 | 1.89 Billion CNY | 7.64% |
| 2018 Q1 | 1.29 Billion CNY | -6.98% |
| 2018 FY | 5.96 Billion CNY | 38.1% |
| 2018 Q3 | 1.54 Billion CNY | 2.79% |
| 2018 Q2 | 1.49 Billion CNY | 15.8% |
| 2018 Q4 | 1.62 Billion CNY | 5.61% |
| 2017 Q3 | 1.16 Billion CNY | 16.0% |
| 2017 FY | 4.31 Billion CNY | 99.51% |
| 2017 Q4 | 1.39 Billion CNY | 19.62% |
| 2017 Q1 | 759.23 Million CNY | 6.05% |
| 2017 Q2 | 1 Billion CNY | 32.16% |
| 2016 Q4 | 715.92 Million CNY | 29.95% |
| 2016 Q1 | 408.27 Million CNY | -18.19% |
| 2016 Q3 | 550.91 Million CNY | 12.53% |
| 2016 FY | 2.16 Billion CNY | 32.91% |
| 2016 Q2 | 489.57 Million CNY | 19.91% |
| 2015 Q2 | 398.84 Million CNY | 26.4% |
| 2015 FY | 1.62 Billion CNY | 19.89% |
| 2015 Q4 | 499.02 Million CNY | 20.18% |
| 2015 Q3 | 415.22 Million CNY | 4.11% |
| 2015 Q1 | 315.54 Million CNY | -20.88% |
| 2014 Q4 | 398.79 Million CNY | 7.97% |
| 2014 Q2 | 336.46 Million CNY | 32.53% |
| 2014 Q3 | 369.35 Million CNY | 9.78% |
| 2014 FY | 1.35 Billion CNY | 32.42% |
| 2014 Q1 | 253.88 Million CNY | 0.0% |
| 2013 FY | 1.02 Billion CNY | 32.83% |
| 2012 FY | 772.33 Million CNY | 22.31% |
| 2011 FY | 631.45 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Joinn Laboratories(China)Co.,Ltd. | 2.37 Billion CNY | -284.912% |
| WuXi AppTec Co., Ltd. | 40.04 Billion CNY | 77.156% |
| Autobio Diagnostics Co., Ltd. | 4.44 Billion CNY | -105.852% |
| Thalys Medical Technology Group Inc. | 2 Billion CNY | -355.97% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 8.53 Billion CNY | -7.117% |
| Chemclin Diagnostics Co., Ltd. | 445.34 Million CNY | -1954.016% |